Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$0.54 USD
+0.04 (8.00%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Sensei Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 37 | 50 | 37 | 19 | 12 |
Income After Depreciation & Amortization | -37 | -50 | -37 | -19 | -12 |
Non-Operating Income | 3 | 2 | 1 | 1 | -2 |
Interest Expense | 0 | 0 | 1 | 2 | 2 |
Pretax Income | -34 | -49 | -37 | -20 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -34 | -49 | -37 | -20 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -34 | -49 | -37 | -20 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -36 | -49 | -37 | -18 | -11 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 2 | 1 |
Income After Depreciation & Amortization | -37 | -50 | -37 | -19 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.95 | 30.70 | 27.71 | 1.61 | NA |
Diluted EPS Before Non-Recurring Items | -1.22 | -1.58 | -1.33 | -12.53 | NA |
Diluted Net EPS (GAAP) | -1.22 | -1.58 | -1.33 | -12.53 | NA |
Fiscal Year end for Sensei Biotherapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.78 | 8.73 | 8.14 | 7.74 | 10.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.78 | -8.73 | -8.14 | -7.74 | -10.17 |
Non-Operating Income | 0.67 | 0.77 | 0.76 | 0.65 | 0.83 |
Interest Expense | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 |
Pretax Income | -7.14 | -7.99 | -7.41 | -7.12 | -9.39 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.14 | -7.99 | -7.41 | -7.12 | -9.39 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.14 | -7.99 | -7.41 | -7.12 | -9.39 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 25.10 | 25.05 | 27.95 | 25.51 | 30.51 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.32 | -0.30 | -0.28 | -0.31 |
Diluted Net EPS (GAAP) | -0.28 | -0.32 | -0.30 | -0.28 | -0.31 |